Garrison L, McDonnell N D
Immunex Corporation, Seattle, WA 98101, USA.
Ann Rheum Dis. 1999 Nov;58 Suppl 1(Suppl 1):I65-9. doi: 10.1136/ard.58.2008.i65.
Tumour necrosis factor (TNF) plays a central part in the pathophysiology of rheumatoid arthritis (RA). TNF initiates signal transduction by interacting with surface bound TNF receptors. Soluble tumour necrosis factor receptors (sTNFRs) act as natural inhibitors of TNF activity. Etanercept, recombinant p75 sTNFR:Fc fusion protein, has received approval from the US Food and Drug Administration for patients with RA and juvenile RA (JRA) who have failed treatment with at least one other drug. Etanercept has demonstrated excellent safety and efficacy in large scale, randomised, double blind, placebo controlled trials of patients with RA and JRA who are refractory to other disease modifying anti-rheumatic drugs. The therapeutic effects mediated by etanercept are rapid and sustained. Combining etanercept with methotrexate was found to be safe and more effective than treatment with methotrexate alone in the treatment of RA. These clinical findings demonstrate that etanercept can result in symptomatic improvement in patients with RA and JRA. Etanercept is an important new addition to the treatment of these diseases.
肿瘤坏死因子（TNF）在类风湿性关节炎（RA）的病理生理学中起核心作用。TNF通过与表面结合的TNF受体相互作用启动信号转导。可溶性肿瘤坏死因子受体（sTNFRs）作为TNF活性的天然抑制剂。依那西普，重组p75 sTNFR:Fc融合蛋白，已获得美国食品药品监督管理局批准，用于至少一种其他药物治疗失败的RA和青少年RA（JRA）患者。在对其他改善病情抗风湿药物难治的RA和JRA患者进行的大规模、随机、双盲、安慰剂对照试验中，依那西普已证明具有出色的安全性和疗效。依那西普介导的治疗效果迅速且持久。在RA治疗中，发现依那西普与甲氨蝶呤联合使用比单独使用甲氨蝶呤更安全、更有效。这些临床研究结果表明，依那西普可使RA和JRA患者症状改善。依那西普是这些疾病治疗中的一项重要新药物。
